Market Review on Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3)
- The report reviews Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (mGluR3 or GRM3 or GPRC1C or MGLUR3) development landscape 

Companies Mentioned

Addex Therapeutics Ltd Domain Therapeutics SA Medgenics, Inc. Prex

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###